At least 13 of 34 patients with acute myeloid leukemia (AML) of varying FAB types were heterozygous for a BamHl restriction fragment length polymorphism (RFLP) of the Ha-ras gene on chromosome 1 1. In 4 of these 13 patients, one allele of the Ha-ras gene was deleted. Two of these cases had an informative heterozygosityfor an RFLP on the long arm of chromosome 11. Analysis of these cases ENES PRESUMED TO be important in the develop-G ment of various human malignancies are thought to act by one of two general mechanisms. One set of genes is characterized as dominantly acting, transforming protooncogenes that are known to be activated by amplification, point mutations, chromosomal rearrangement, or overexpression. A second set of genes are those in which tumor predisposing mutations are recessive to wild type alleles, and for which loss of the normal allele is necessary to unmask the mutation and promote tumor development. The occurrence of gene loss can be studied by the use of restriction fragment length polymorphisms ( 
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MATERIALS AND METHODS
Bone marrow and/or peripheral blood samples (if blast cell count exceeded 60%) from 34 AML patients and other hematologic malignancies were collected after informed consent and kept frozen at -70°. The diagnosis of AML was based on standard clinical and hematologic criteria and patients were classified according to the FAB classification. The phenotype of the blast cells was confirmed as myeloid by histochemistry and a positive reactivity to either or both myeloid-specific monoclonal antibodies (MoAbs), GM 58/8 and/or 1G10. 24 No reactivity was seen with the lymphoid-specific antibodies CD1, CD3, CD4, CDS, CD6, CD8, and CDlO, or with heteroantisera for terminal deoxynucleotidyl transferase (TdT). Normal tissue, in the form of skin biopsies, was obtained from six of these patients after informed consent, and was kept frozen at -7OOC pending further analysis. Genomic DNA was extracted using cesium chloride density gradient ultra centrifugation or proteinase K digestion and subsequent phenol/ chloroform extraction, and cut with restriction endonucleases appropriate to the gene being studiedSz5 The resulting fragments were separated by electrophoresis on 0.8% agarose gels and transferred to Zetraprobe R membranes (Bio-Rad, Richmond, CA). The relevant probes" were labeled to a high specific activity by the random primer labeling methodz6 and were used to hybridize these filters. After washing as specified by the manufacturer, filters were dried, and autoradiographs made with a Kodak intensifying screen and were inspected for amplification, deletion, and rearrangements of the bands.
A 100 base pair (bp) fragment encompassing exon-1 and a 104 bp fragment from exon-2 of the Ha-ras gene were amplified by the polymerase chain reaction (PCR) by using 20 bp synthetic oligodeoxynucleotides spanning the 5' and 3' ends and thermostable Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT) by a modification of the method described by Saiki et The mixture was incubated at 95OC for 1 minute to denature the DNA, cooled to W C for 30 seconds to allow primer annealing, followed by extension at 72OC for 90 seconds. This cycle was repeated 30 times in a Perkin Elmer Cetus DNA thermal cycler.
The two amplified fragments were electrophoresed on 3% Nusieve gels (FMC Bioproducts; Rockland, ME), sliced from the gel, electroeluted, purified on Elutip-D columns (Schleicher and Schnell, Keene, NH), and ethanol precipitated. Sequencing primers were end-labeled with [y-3zP]-adenosine triphosphate (ATP) (Amersham; Arlington Heights, IL) and T4 polynucleotide kinase (BRL) and annealed to the amplified fragment, which was denatured at 95OC for 10 minutes and quickly chilled on ice. The reaction mixture (10 pL) was divided into four tubes containing 2 pL of cold dNTPs and ddNTPs (Pharmacia, Piscataway, NJ) (ratio of 1O:l) and T7 DNA DNA extraction and Southern blot hybridization.
Polymerase chain reaction and sequencing. The human Hu-rus gene demonstrates a BumHI RFLP. DNA sequence data suggest that the basis for this polymorphism is a region of tandemly repeated nucleotides closely linked to the coding sequence at the 3' end." This structural feature is responsible for the generation of many allelic restriction fragments at the Ha-rus locus ranging in size from 6.6 to 8 kilobases (kb) (Fig 1) .
In 13 of the 34 patients, two bands were detected indicating heterozygosity for the BumHI RFLP. All except four patients demonstrated the anticipated approximately equal intensities of the two polymorphic bands, indicating that both alleles were present in approximately equal concentrations. In the four patients the signal intensity from one of the alleles was reduced considerably compared with the other, suggesting loss of one allele in these cells (Fig lA,B , lane c; C, lanes d and j). The faint residual signal of one allele in these cells presumably originated in contaminating nonleukemic cells or in a clone of leukemic cells that had not lost one Ha-ras allele. Normal tissue in the form of skin biopsies was analyzed from six patients, including one showing an apparent loss of one allele. While the pattern of the Ha-ras alleles was similar in the paired malignant and normal tissue in five of these patients, the one patient with an apparent loss of one allele was clearly heterozygous in his normal tissue, thereby confirming loss of one allele (Fig 1A) . Although normal tissue was not available from the three other cases with disproportionate intensities of the two polymorphic bands, we infer that these samples contain malignant cells that have lost one allele for several reasons. First, in our analysis of normal tissue from over 50 patients with various forms of cancer and normal healthy subjects, we failed to detect such a pattern in any of these samples. Second, in 33 patients in whom paired normal and tumor tissue was available, the decreased relative intensity of one of the polymorphyic bands in tumor tissue was always indicative of an allelic deletion.I2 Third, a partial digestion as a cause of the abnormal intensity was ruled out by probing the same blots with four different probes and in each instance, only the expected germ-line bands were detected. Finally, similar results have been interpreted as indicating an allelic loss by other investigators."
In order to explore whether the allelic deletion of Ha-rus involved only loci on the short arm of chromosome 11 or loss of the entire chromosome, we used a proto-oncogene probe (INT-2) that detects sequences on the long arm at locus 1 lq13 and that has an RFLP for the enzyme BumHLz9 In two relevant and informative cases with loss of one allele of Ha-rus. there was no evidence for loss of sequences on the long arm of chromosome 11 (data not shown).
Although allelic loss at the Ha-rus locus is frequently detected in several embryonal and adult tumors," thus far, AML is the only hematologic malignancy showing this abnormality. In our own analysis, other malignancies, including 15 cases of blast crisis of chronic myelogenous leukemia (CML) (six heterozygous), 24 cases of acute lymphocytic leukemia (12 heterozygous), 8 cases of multiple myeloma (six heterozygous), six cases of Hodgkin's disease (one heterozygous), and 13 cases of myelodysplastic syndrome (four heterozygous), failed to show allelic deletion in the Ha-rus locus by RFLP analysis. Interestingly, three AML cases showing allelic loss of the Ha-rus gene were classified as AML of the M 1 type, and one was of the M2 type.
Loss of one allele of a proto-oncogene raises the possibility
that the remaining allele is structurally altered. In order to examine the possibility that the remaining allele was mutated in the three cases with allelic deletions, we sequenced DNA segments from exons 1 and 2 of Ha-ras encompassing codons 1 through 34 and 39 through 73, since the common sites of mutation are at codons 12, 13, and 61. We used a recently developed technique in which DNA amplified in vitro by PCR is sequenced (see Materials and Methods). This technique allows the detection of mutant alleles when present in 20% or more of the cells (mixing experiments; H. Ahuja, N. Gonzalez-Cadavid, and M.J. Cline, unpublished observations, August 1988). No mutations were seen a t any of the above residues in these cases, indicating that the remaining Ha-ras allele was structurally normal at the sites.
DISCUSSION
This study shows that many of the previously described changes in proto-oncogenes and growth factor genes occur infrequently in AML, while the analysis of allelic restriction fragments of the Ha-ras gene demonstrates a relatively frequent loss of genes on the short arm of chromosome 11 in AML. Loss of this chromosomal segment seems to be particularly common in the M1 variant of AML. This observation extends the list of human malignancies that show loss of genes at this site, a list which has previously included Wilms' embryonal rhabdomyosarcoma,' and several adult solid tumors. 12 At present, the significance of loss of the Ha-ras gene is not clear. It is possible that loss of one allele of the Ha-ras locus serves merely as a marker for loss of other genes located on the short arm of chromosome 11 and that such genes act predominantly as "cancer suppressor" genes. Evidence for the existence of a suppressor gene on chromosome 11 has been provided by studies wherein introduction of a normal chromosome 1 1 by microcell fusion with a Wilms' tumor cell line controlled its tumorigenic expre~sion.~' An alternative explanation of the significance of the allelic deletion of Ha-ras is that the remaining allele of the Although the biologic meaning of allelic loss a t the Ha-ras locus remains to be elucidated, its restriction to the most undifferentiated form of AML and its absence in the more differentiated forms suggests that the affected gene(s) or its product play an important role in the orchestrated events that take place during hematopoiesis. It is unlikely that the loss of gene sequences on chromosome 11 represents the only mechanism involved in the genesis of AML. Approximately 25% of patients with AML have mutated versions of N-ras genes. Also, most patients with AML have nonrandom chromosomal abnormalities that are distant from either the sites of the N-ras gene or the short arm of chromosome 1 1. It is likely, therefore, that loss of genes on the short arm of chromosome 11 represents one of the many genetic changes in the multi-step pathway of leukemogenesis.
